Additionally, medications in the pipeline for NASH, including GLP-1RAs and PPAR modulators can augment the production of endogenous adiponectin and decrease TNF-α concentrations, being potentially beneficial as add-on to ICIs. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatohepatitis.